PDS Biotechnology Corporation (PDSB)
Nasdaq · Healthcare · Biotechnology
$1.20+60.32%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $87.0M
- 52-week range
- $0.195 – $1.55
- 52-week change
- −22.30%
- EPS (trailing)
- −$0.64
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$34.5M
- Diluted EPS
- −$0.74
- Free cash flow
- −$27.8M
From the company’s annual report on SEC EDGAR.
About PDS Biotechnology Corporation
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH.
Headquarters: Princeton, United States · 21 employees · pdsbiotech.com